Agilent Technologies (NYSE:A) Given New $145.00 Price Target at Barclays

Agilent Technologies (NYSE:A) had its target price hoisted by Barclays from $140.00 to $145.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price points to a potential upside of 7.43% from the company’s current price.

Several other research analysts also recently commented on A. Wall Street Zen downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. UBS Group reduced their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Bank of America raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $150.00 to $145.00 in a research note on Thursday. Morgan Stanley reduced their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Finally, TD Cowen reduced their price objective on shares of Agilent Technologies from $170.00 to $157.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $161.07.

Agilent Technologies Trading Up 16.5%

A traded up $19.13 during trading on Thursday, hitting $134.97. 2,082,453 shares of the stock were exchanged, compared to its average volume of 2,184,981. The firm has a 50 day simple moving average of $114.99 and a 200 day simple moving average of $128.79. The firm has a market cap of $38.14 billion, a price-to-earnings ratio of 29.70, a P/E/G ratio of 2.42 and a beta of 1.22. Agilent Technologies has a 1 year low of $108.35 and a 1 year high of $160.27. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.59 and a current ratio of 2.07.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.80 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.Agilent Technologies’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. As a group, equities analysts expect that Agilent Technologies will post 5.95 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Core Wealth Advisors LLC acquired a new position in Agilent Technologies in the 4th quarter valued at $26,000. SHP Wealth Management acquired a new position in Agilent Technologies in the 4th quarter valued at $26,000. Board of the Pension Protection Fund acquired a new position in Agilent Technologies in the 4th quarter valued at $27,000. Navalign LLC acquired a new position in Agilent Technologies in the 4th quarter valued at $27,000. Finally, Cedar Mountain Advisors LLC acquired a new position in Agilent Technologies in the 1st quarter valued at $27,000.

Agilent Technologies News Summary

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent beat Wall Street’s Q2 expectations, reporting adjusted EPS of $1.49 versus estimates around $1.41 and revenue of $1.83 billion, above forecasts, with revenue up 10% year over year. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 profit outlook and also issued Q3 guidance that points to continued growth, reinforcing confidence in demand for its lab tools and diagnostic products. Agilent raises 2026 profit forecast on strong demand for lab tools
• Positive Sentiment: Bank of America upgraded Agilent from neutral to buy, which typically helps sentiment because it signals improved confidence in the stock’s upside. Benzinga report on Bank of America upgrade
• Positive Sentiment: RBC also initiated coverage with an outperform rating and a $153 price target, adding another bullish analyst call after earnings. Benzinga report on RBC coverage
• Neutral Sentiment: Agilent also highlighted new product launches and digital-lab tools, including OpenLab Sync and new GC systems, which support the longer-term growth story but are less likely to move the stock immediately. Agilent Introduces OpenLab Sync

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.